Patient-reported outcomes from a randomized trial of neoadjuvant atezolizumab-chemotherapy in early triple-negative breast cancer

Patient-reported outcomes data assessing patients’ experience of immunotherapy treatment burden in potentially curable early-stage triple-negative breast cancer (TNBC) are lacking. These patient-reported data inform clinical benefit and decision-making for adding atezolizumab to neoadjuvant chemothe...

Descripción completa

Detalles Bibliográficos
Autores principales: Barrios, Carlos H., Saji, Shigehira, Harbeck, Nadia, Zhang, Hong, Jung, Kyung H., Patel, Sheetal, Patel, Shilpen, Duc, Anh Nguyen, Liste-Hermoso, Mario, Chui, Stephen Y., Mittendorf, Elizabeth A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9485121/
https://www.ncbi.nlm.nih.gov/pubmed/36123366
http://dx.doi.org/10.1038/s41523-022-00457-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9485121/
https://www.ncbi.nlm.nih.gov/pubmed/36123366
http://dx.doi.org/10.1038/s41523-022-00457-3

Ejemplares similares